查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961258

癌症奈米技術市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

Cancer Nanotechnology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症奈米技術市場預計將從 2025 年的 380.5 億美元大幅成長至 2031 年的 650.5 億美元，複合年成長率為 9.35%。

該領域致力於利用奈米裝置和顆粒實現對惡性腫瘤的高精度診斷、成像和治療。其主要成長要素包括：迫切需要標靶藥物遞送系統以最大程度地降低傳統化療相關的全身毒性，以及早期檢測能力日益重要。癌症發生率的上升進一步推動了這一成長趨勢。根據美國癌症協會預測，美國新增癌症病例數預計在2024年首次超過200萬例，凸顯了奈米醫學在改善治療效果方面的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 380.5億美元
市場規模：2031年 650.5億美元
複合年成長率：2026-2031年 9.35%
成長最快的細分市場 乳癌
最大的市場 北美洲

儘管取得了這些進展，但由於研發和治療高成本，市場仍面臨許多挑戰，這構成了主要的進入門檻。此外，奈米材料安全性的監管複雜性也常延長核准流程。患者的經濟負擔十分沉重；根據美國癌症研究協會 (AACR) 2024 年的一份報告，美國超過 40% 的癌症患者在開始治療後的短短兩年內就會耗盡畢生積蓄。這種經濟負擔嚴重阻礙了這些先進技術的廣泛應用，並可能限制整體市場成長。

市場促進因素

推動市場加速發展的主要動力之一是製藥業內部日益增多的策略聯盟，這些聯盟正在加速複雜奈米藥物平台的商業化進程。領先的製藥公司正積極尋求併購，將先進的標靶遞送機制整合到其癌症治療產品線中，確保臨床成功所需的技術基礎。這些聯盟使每家公司都能利用其獨特的合成生物學和偶聯技術來提高治療的精確度。強生公司擴展其標靶癌症治療能力就清晰地展現了這種整合趨勢。 2024年1月，強生公司宣布收購Ambrax公司，雙方已達成一項價值約20億美元的最終協議，收購Ambrax BioPharma公司用於新一代抗體藥物偶聯物（ADC）的專有平台。

同時，政府和私人部門對研發投入的激增，正成為診斷和治療奈米技術創新發展的關鍵催化劑。公共部門的努力在降低早期技術風險以及支持旨在透過先進成像技術改善腫瘤可視化和手術效果的計劃發揮著至關重要的作用。近期一項旨在創新癌症手術的聯邦津貼反映了這種資金投入。根據白宮2024年9月發布的一份情況說明書，美國高級醫學研究計畫署（ARPA-H）向一個開發新技術（例如用於提高手術精度的顯微成像系統）的團隊撥款1.5億美元。這筆資金的流入是為了回應由長期流行病學預測驅動的日益成長的全球需求。世界衛生組織（WHO）在2024年報告稱，國際癌症研究機構（IARC）預測，到2050年，全球癌症新增病例將超過3500萬例，這凸顯了對可擴展奈米技術解決方案的迫切需求。

市場挑戰

全球癌症奈米技術市場的擴張直接受到研發和治療相關高昂成本的限制，這些成本構成了巨大的財務障礙。奈米顆粒的製造需要複雜的工程技術和精密製造程序，導致其研發成本遠高於傳統藥物。這些資本密集要求阻礙了中小型生物技術公司的投資，增加了現有公司的財務風險，並延緩了有前景的奈米藥物從臨床試驗到商業化的進程。

因此，這些飆升的研發成本最終會轉嫁到市場價格上，這對患者和醫療保健系統都帶來了沉重的經濟負擔。這種經濟負擔限制了先進奈米療法的普及，因為保險公司和公共衛生計畫難以將這些昂貴的療法納入現有預算。根據歐洲製藥工業協會聯合會（EFPIA）統計，2023年歐洲癌症治療的直接成本達到1,460億歐元，凸顯了醫療保健支出面臨的巨大壓力。如此沉重的經濟負擔導致了嚴格的報銷政策和市場進入限制，儘管人們對這些創新技術的治療效果寄予厚望，但實際上卻阻礙了商業性發展。

市場趨勢

隨著人工智慧（AI）融入奈米顆粒設計，癌症奈米藥物的研發正經歷一場根本性的變革。這種從試驗的合成方法到預測性計算建模的轉變，有效解決了奈米載體設計固有的複雜性。在這個領域，即使是微小的成分變化也會顯著影響治療效果和毒性，而利用機器學習演算法可以在實際製造之前模擬奈米顆粒與生物環境的相互作用，從而最佳化藥物負載量和靶向精度。計算效率的提升顯著加快了藥物發現進程。如同News-Medical.net網站2025年9月發表的題為「AI引導平台提升治療性奈米顆粒的設計與效率」的報導所述，研究人員利用AI驅動模型，將奈米顆粒的製備成功率提高了42.9%，遠超標準方法，充分展現了該技術克服製劑瓶頸的能力。

同時，市場正經歷著向免疫奈米療法的關鍵轉型，其顯著特徵是脂質奈米顆粒（LNP）的應用範圍不斷擴大，從感染疾病疫苗擴展到個人化癌症治療。這一趨勢強調開發先進的LNP載體，旨在將mRNA癌症疫苗和基因編輯有效載荷直接遞送至腫瘤部位或免疫細胞，從而誘導強效的全身性免疫反應。這些平台的商業性潛力正推動著產業進行大量投資，旨在提高核酸遞送系統的穩定性和組織特異性。這項轉型的經濟規模顯而易見，預計到2032年，全球脂質奈米顆粒市場規模將達到23億美元。 2025年9月，贏創宣布與Etris建立策略夥伴關係。這主要得益於腫瘤領域對核酸療法的需求不斷成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球癌症奈米技術市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（奈米顆粒、奈米纖維、奈米棒、石墨烯、奈米流體裝置、其他）
    • 依應用領域（乳癌、胃癌、肺癌等）
    • 依最終使用者（診斷、治療、治療診斷）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美癌症奈米技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲癌症奈米技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區癌症奈米技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲癌症奈米技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲癌症奈米技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球癌症奈米技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Ltd.
  • GE Healthcare Inc.
  • Combimatrix Corporation.
  • Mallinckrodt Plc
  • Sigma-Tau Pharmaceuticals Inc.
  • Merck and Company Inc.
  • Pfizer, Inc.
  • Nanosphere, Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20163

The Global Cancer Nanotechnology Market is projected to expand significantly, rising from a valuation of USD 38.05 Billion in 2025 to USD 65.05 Billion by 2031, reflecting a compound annual growth rate of 9.35%. This sector focuses on utilizing nanoscale devices and particles to achieve high-precision diagnosis, imaging, and treatment of malignancies. Key growth drivers include the urgent demand for targeted drug delivery systems capable of minimizing the systemic toxicity associated with traditional chemotherapy, alongside the critical need for early detection capabilities. This upward trajectory is further underpinned by the increasing incidence of cancer; according to the American Cancer Society, the number of new cancer diagnoses in the United States was projected to surpass 2 million for the first time in 2024, highlighting the immediate necessity for the enhanced therapeutic efficacy provided by nanomedicine.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 38.05 Billion
Market Size 2031USD 65.05 Billion
CAGR 2026-20319.35%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

Despite these advancements, the market faces significant hurdles due to the high costs associated with development and treatment, which create substantial financial barriers to entry. Additionally, regulatory complexities related to the safety of nanomaterials often result in prolonged approval processes. The economic burden on patients is profound; the American Association for Cancer Research reported in 2024 that over 40% of cancer patients in the United States deplete their life savings within just two years of commencing treatment. This financial toxicity poses a serious threat to the widespread adoption of these advanced technologies and could potentially constrain overall market growth.

Market Driver

A primary engine for market acceleration is the increase in strategic collaborations within the pharmaceutical industry, which facilitates the commercialization of complex nanomedicine platforms. Major pharmaceutical companies are actively pursuing mergers and acquisitions to incorporate advanced targeted delivery mechanisms into their oncology pipelines, thereby securing the necessary technical infrastructure for clinical success. These partnerships enable firms to utilize proprietary synthetic biology and conjugation technologies to refine the precision of therapeutic agents. This trend of consolidation was clearly demonstrated when Johnson & Johnson expanded its targeted oncology capabilities; according to a January 2024 announcement regarding the "Johnson & Johnson to Acquire Ambrx" deal, the company entered a definitive agreement valued at approximately $2.0 billion to obtain Ambrx Biopharma's proprietary platform for next-generation antibody-drug conjugates.

Concurrently, a surge in government funding and private capital for research and development is acting as a vital catalyst for innovation in diagnostic and therapeutic nanotechnology. Public sector initiatives play a crucial role in de-risking early-stage technologies and supporting projects designed to enhance tumor visualization and surgical outcomes through advanced imaging. This financial backing is illustrated by recent federal grants aimed at revolutionizing cancer surgery; according to a September 2024 White House "Fact Sheet," the Advanced Research Projects Agency for Health (ARPA-H) awarded $150 million to teams developing novel technologies, such as microscopic imaging systems, to increase surgical precision. This influx of capital addresses a growing global need driven by long-term epidemiological forecasts; the World Health Organization reported in 2024 that the International Agency for Research on Cancer expects the global cancer burden to exceed 35 million new cases by 2050, creating an urgent mandate for scalable nanotechnological solutions.

Market Challenge

The expansion of the Global Cancer Nanotechnology Market is directly impeded by the exorbitant costs associated with development and treatment, which establish significant financial obstacles. The creation of nanoscale particles demands intricate engineering and precision manufacturing, resulting in research and development expenses that are considerably higher than those for conventional pharmaceuticals. These capital-intensive requirements discourage investment from smaller biotechnology firms and heighten financial risks for established entities, often leading to delays in moving promising nanomedicines from clinical trials to commercial availability.

As a result, these elevated development costs are passed on to the final market price, placing a severe economic strain on both patients and healthcare systems. This financial burden limits the widespread adoption of advanced nanotherapeutics, as insurers and public health programs struggle to incorporate these costly treatments into their existing budgets. According to the European Federation of Pharmaceutical Industries and Associations, the direct costs of cancer care across Europe reached €146 billion in 2023, highlighting the immense pressure on healthcare expenditures. Such intense financial toxicity leads to strict reimbursement policies and restricted market access, effectively stifling the commercial growth of these innovative technologies despite their therapeutic promise.

Market Trends

The development of cancer nanomedicines is being fundamentally transformed by the integration of artificial intelligence into nanoparticle design, moving away from trial-and-error synthesis toward predictive computational modeling. This shift addresses the inherent complexity of engineering nanoscale carriers, where even minor compositional changes can drastically affect therapeutic efficacy and toxicity. By employing machine learning algorithms, researchers can simulate interactions between nanoparticles and biological environments to optimize drug loading and targeting precision prior to physical manufacturing. This computational efficiency significantly speeds up the discovery pipeline; as reported by News-Medical.net in a September 2025 article titled "AI-guided platform improves design and efficiency of therapeutic nanoparticles," researchers using an AI-driven model realized a 42.9% increase in successful nanoparticle formation rates compared to standard methods, confirming the technology's ability to resolve formulation bottlenecks.

In parallel, the market is undergoing a decisive transition toward immuno-nanomedicine, characterized specifically by the expansion of lipid nanoparticles (LNPs) from infectious disease vaccines to personalized oncology applications. This trend emphasizes the engineering of sophisticated LNP vehicles designed to deliver mRNA cancer vaccines and gene-editing payloads directly to tumor sites or immune cells, thereby eliciting a potent systemic response. The commercial potential of these platforms is stimulating significant industrial investment aimed at improving the stability and tissue-specificity of nucleic acid delivery systems. The economic scale of this shift is clear; according to a September 2025 announcement by Evonik regarding their strategic partnership with Ethris, the global lipid nanoparticle market is projected to reach $2.3 billion by 2032, largely fueled by the rising demand for nucleic acid-based therapies in the oncology sector.

Key Market Players

  • Abbott Laboratories Ltd.
  • GE Healthcare Inc.
  • Combimatrix Corporation.
  • Mallinckrodt Plc
  • Sigma-Tau Pharmaceuticals Inc.
  • Merck and Company Inc.
  • Pfizer, Inc.
  • Nanosphere, Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries

Report Scope

In this report, the Global Cancer Nanotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Nanotechnology Market, By Type

  • Nanoparticles
  • Nanofibers
  • Nanorods
  • Graphene
  • Nanofluidic Devices
  • Others

Cancer Nanotechnology Market, By Application

  • Breast Cancer
  • Stomach Cancer
  • Lung Cancer
  • Others

Cancer Nanotechnology Market, By End User

  • Diagnostics
  • Therapeutics
  • Theranostics

Cancer Nanotechnology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Nanotechnology Market.

Available Customizations:

Global Cancer Nanotechnology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Nanotechnology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
    • 5.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
    • 5.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Nanotechnology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Nanotechnology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Cancer Nanotechnology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Cancer Nanotechnology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Cancer Nanotechnology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Nanotechnology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Cancer Nanotechnology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Cancer Nanotechnology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Cancer Nanotechnology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Cancer Nanotechnology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Cancer Nanotechnology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Nanotechnology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Cancer Nanotechnology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Cancer Nanotechnology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Cancer Nanotechnology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Cancer Nanotechnology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Cancer Nanotechnology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Nanotechnology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Cancer Nanotechnology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Cancer Nanotechnology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Cancer Nanotechnology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Nanotechnology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Cancer Nanotechnology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Cancer Nanotechnology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Nanotechnology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GE Healthcare Inc.
  • 15.3. Combimatrix Corporation.
  • 15.4. Mallinckrodt Plc
  • 15.5. Sigma-Tau Pharmaceuticals Inc.
  • 15.6. Merck and Company Inc.
  • 15.7. Pfizer, Inc.
  • 15.8. Nanosphere, Inc.
  • 15.9. Celgene Corporation
  • 15.10. Teva Pharmaceutical Industries

16. Strategic Recommendations

17. About Us & Disclaimer